The Global Ventricular Tachycardia Market is estimated to be valued at USD 15.52 Bn in 2025 and is expected to reach USD 22.28 Bn by 2032, reflecting a compound annual growth rate (CAGR) of 5.3% from ...

The topical anesthetic is a longtime Hollywood styling secret—but does it actually work?

Dr Emma Svennberg, cardiologist in Stockholm and first author of the consensus paper, noted that modern AF care requires a more streamlined and holistic approach. She highlighted the need to address ...

The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

HUYABIO International today announced favorable Phase 1 clinical data for HBI-3000, a novel bioinspired investigational drug with promising antiarrhythmic properties, excellent tolerability and a ...

CLINICAL QUESTION: Among patients with ischemic cardiomyopathy and ventricular tachycardia, is catheter ablation or antiarrhythmic drug therapy a more effective initial strategy BACKGROUND: ...

Madrid, Spain – 31 August 2025: Pulsed field ablation did not have superior efficacy to radiofrequency ablation in patients with drug-resistant paroxysmal (intermittent) atrial fibrillation, according ...

When it comes to preventing recurrences of atrial tachyarrhythmias in patients with atrial fibrillation (AF) and obesity, catheter ablation tops a combination of lifestyle modifications and ...

Incident atrial fibrillation (AF) is common among adults with kidney failure treated with maintenance dialysis and is associated with poor clinical outcomes. Limited data exist informing treatment of ...

There are improved all-cause mortality, rhythm control, and adverse cardiac event outcomes in patients being treated with tirzepatide who have atrial fibrillation. Patients with atrial fibrillation ...